Novartis Delivers Strong Innovation in 2012, Offsetting Patent Expirations …
Novartis delivers strong innovation in 2012, offsetting patent expirations …
Filed under: dual diagnosis treatment centers
The results showed that both newly diagnosed patients and those switching to Tasigna after long-term treatment with Glivec achieved deeper molecular response with Tasigna. A robust clinical trial program evaluating the … By leveraging our scale …
Source
Related Dual Diagnosis Treatment Centers Information…